Who makes BI 10773 - single rising dose?

BI 10773 - single rising dose is developed by Boehringer Ingelheim.

What development phase is BI 10773 - single rising dose in?

BI 10773 - single rising dose is in Phase 1.

Last reviewed 2026-04-20 · How we verify

BI 10773 - single rising dose

Boehringer Ingelheim · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	BI 10773 - single rising dose
Sponsor	Boehringer Ingelheim
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BI 10773 - single rising dose CI brief — competitive landscape report
BI 10773 - single rising dose updates RSS · CI watch RSS
Boehringer Ingelheim portfolio CI